Loading news...
Imunon (NASDAQ: IMNN - Get Free Report) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Imunon to post earnings of ($1.54) per share for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for
Imunon (NASDAQ: IMNN - Get Free Report) and Pharma Mar (OTCMKTS:PHMMF - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Valuation and Earnings This table compares Imunon and Pharma
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing LAWRENCEVILLE, N.J.
Imunon (NASDAQ: IMNN - Get Free Report) and Allogene Therapeutics (NASDAQ: ALLO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations. Profitability This table compares Imunon and Allogene Therapeutics'
Shares of Imunon, Inc. (NASDAQ: IMNN - Get Free Report) have earned a consensus rating of "Hold" from the five analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the
LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,939,114 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate of 1,939,114 shares of common stock, in a registered direct offering priced at-the-market under Nasdaq rules.
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) Dear Valued Shareholders, 2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovarian Cancer Treatment As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data validation, and strategic execution that has significantly strengthened IMUNON's position.
Imunon, Inc. (NASDAQ: IMNN - Get Free Report)'s share price shot up 5.3% on Wednesday. The stock traded as high as $4.35 and last traded at $4.18. 117,956 shares were traded during mid-day trading, an increase of 276% from the average session volume of 31,393 shares. The stock had previously closed at $3.97. Analysts Set
Imunon, Inc. ( IMNN ) Q3 2025 Earnings Call November 13, 2025 11:00 AM EST Company Participants Stacy Lindborg - President, CEO & Director Douglas V. Faller - Chief Medical Officer Kimberly Graper - CFO and Principal Financial & Accounting Officer Khursheed Anwer - Executive VP & Chief Scientific Officer Conference Call Participants David Bautz - Zacks Small-Cap Research James Molloy - Alliance Global Partners, Research Division Emily Bodnar - H.C.
R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer
Imunon, Inc. ( IMNN ) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study November 10, 2025 8:00 AM EST Company Participants Stacy Lindborg - President, CEO & Director Douglas V. Faller - Chief Medical Officer Conference Call Participants Premal Thaker Amir Jazaeri Giorgio Paulon James Molloy - Alliance Global Partners, Research Division Emily Bodnar - H.C.
Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today hosted a compelling public webcast, where cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 minimal residual disease (MRD) trials, clinicians, statistical experts and IMUNON executives shared critical insights into the disease and translational data, along with compelling clinical data highlighting the significant potential of IMNN-001 for women with advanced ovarian cancer.
Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, analysts and those interested in advances in ovarian cancer treatment and women's health are encouraged to attend, either In-person or virtually LAWRENCEVILLE, N.J.
Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET
LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m.
Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, 2025
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has been invited to present a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, at the 2025 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS), being held November 5-7, 2025 in Cape Town, South Africa.
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that new translational data from the Phase 2 OVATION 2 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, being held November 5-9, 2025 in National Harbor, Maryland.
Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025 Program will feature presentations from ovarian cancer thought leaders, Phase 3 study investigators, oncology and statistical experts LAWRENCEVILLE, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it will host an R&D Day for investors at the Harvard Club (35 West 44th Street) in New York City on November 10, 2025, beginning at 8:00 a.m.
Company seeks strategic partners to advance novel PlaCCine technology LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform's potential as a next-generation vaccine, today announced that members of its leadership team will deliver oral presentations highlighting IMNN-101, its investigational DNA plasmid vaccine based on the Company's proprietary PlaCCine® technology platform, including proof-of-concept clinical trial results at the following upcoming vaccine conferences: 5th Edition of International Vaccines Congress (IVC) Keynote Oral Presentation Title: A promising novel approach to DNA vaccines Presenting Author: Khursheed Anwer, Ph.D.